Human Chorionic Gonadotropin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

Over the next few years, the human chorionic gonadotropin market is expected to register a CAGR of about 7.6%.

Due to COVID-19 restrictions worldwide, foot traffic in hospitals and clinics decreased significantly, negatively impacting the growth of the human chorionic gonadotropin market. For instance, according to the research study published by Frontiers Media S.A. in April 2022, many infertile patients decided not to request assisted reproductive technology (ART) treatments due to the pandemic. During the pandemic, there was a decline in the number of concluded ART cycles as compared to the preceding year (749 vs. 844 cycles). This decline, despite the unchanged availability of ART services, is attributed to many factors: the local restrictions and the fear of SARS-Cov-2 infection and potential adverse obstetric outcomes did not encourage physicians and patients to engage in ART. Although, with the ongoing vaccinations and decreasing cases of COVID-19, the market is expected to regain normalcy over the coming years.

The growth of the human chorionic gonadotropin (HCG) market is attributed to the increasing prevalence of infertility and hypogonadism, changing lifestyles, and increased awareness regarding infertility treatment. Hypogonadism, for example, is characterized by low serum testosterone concentration, which is followed by a number of clinical features such as erectile dysfunction (ED), poor morning erections, low libido, memory loss, physical decline in strength and health, difficulty concentrating, and depression.According to the study published by BMC Endocrine Disorders in July 2021, erectile dysfunction was found to be prevalent in 72.2% of people globally in 2021. Furthermore, according to the CDC update in March 2022, about 1 in 5 (22%) couples in which the woman is 30-39 have problems conceiving their first child, compared to about 1 in 8 (13%) couples in which the woman is younger than 30. Age-related fertility loss is mostly caused by deteriorating egg quality. Older women also have fewer remaining eggs and are more likely to have health issues that can affect fertility. Aging also increases a woman’s chances of miscarriage and of having a child with a genetic abnormality. Therefore, the high burden of infertility is also raising the demand for effective treatments such as human chorionic gonadotropin (HCG) hormones, which is fueling the market's growth.

In addition, increasing awareness about HCG among healthcare professionals and patients, coupled with the new product launches, is anticipated to boost the market’s growth over the forecast period. Human chorionic gonadotropin is used as a marker in cancer, including choriocarcinoma, seminoma, and germ cell tumors, which may augment the market’s growth over the coming years with the increasing cases of cancer. For example, as per the article published in January 2020 by David G. Grenache, HCG was initially developed as a test for pregnancy. But HCG is now commonly used to test women who might have an ectopic pregnancy, along with other biomarkers, to look for fetal aneuploidies and as a tumor marker for a wide range of neoplasms.

Therefore, the factors mentioned above are attributed collectively to the studied market's growth over the forecast period. However, the availability of substitutes is expected to hinder market growth over the forecast period.

Human Chorionic Gonadotropin Market Trends

Female Infertility Treatment Segment is Anticipated to Grow at a Significant Rate Over the Forecast Period

Infertility is defined as the inability of the couple to get pregnant or the inability of the woman to carry a pregnancy to term. As the human chorionic gonadotropin (HCG) hormone plays a vital role after the formation of the embryo during pregnancy, the use of HCG in infertility treatment has gained traction in both men and women. Infertility in females can be caused by different reasons. According to the World Health Organization, the primary factors include tubal disorders like a blocked fallopian tube, uterine diseases, polycystic ovarian syndrome (PCOS), other follicular disorders, and endocrine system disorders. With the growing burden of infertility in females worldwide, the demand for effective treatment is increasing, which is expected to drive the segment's growth over the forecast period. According to a research study published by the National Library of Medicine in December 2021, the overall prevalence of infertility was 24.58%, with 6.54% of women experiencing primary infertility and 18.04% experiencing secondary infertility.Thus, due to the high prevalence of infertility among women, the use of HCG is expected to increase over the coming years, thus driving the market’s growth.

Further, the recombinant human chorionic gonadotropin products are anticipated to have significant growth due to the availability of different strengths and dosages for the individualization of therapy. Demand for naturally extracted HCG hormone products is also going up because new products are coming out and people are using them more. This could help the segment grow over the next few years.

North America is Expected to Dominate the Human Chorionic Gonadotropin Market Over the Forecast Period

North America is anticipated to have significant market growth over the forecast period. The increase may be attributed to well-established healthcare infrastructure, favorable reimbursement policies, and the growing burden of infertility in the region.

According to the March 2022 update of the Centers for Disease Control and Prevention (CDC), in the United States, among heterosexual women aged 15-49 years with no prior births, about 1 in 5 (19%) are unable to get pregnant after one year of trying (infertility). Also, about 1 in 4 (26%) women in this group have difficulty getting pregnant or carrying a pregnancy to term (impaired fecundity). Furthermore, according to the WHO 2022 update, 15% of reproductive-aged couples worldwide are affected by infertility. This data shows a prevalence of infertility and impaired fecundity in the region, which may drive the demand for HCG for infertility treatment in the country, thus boosting the market’s growth in North America.

With rising awareness about infertility and its associated factors, the growing adoption of assisted reproductive technology (ART), and the development and acquisition of market players, the human chorionic gonadotropin (HCG) market is expected to grow further during the forecast period. For instance, in November 2021, InsurMedix, an AI-powered insurance platform, closed a USD 65 million funding round to provide coverage for fertility treatments. The platform, launched in the United States in early 2022, offers medical insurance for reproductive treatments and offers coverage for complementary and alternative medicine as well as medical tourism for care received outside of the country. As a result, these changes are likely to help the market grow in the region over the next few years.

Human Chorionic Gonadotropin Market Competitor Analysis

The human chorionic gonadotropin market is moderate due to the presence of companies operating globally and regionally. The competitive landscape includes an analysis of international and local companies that hold market shares and are well known, including Merck KGaA, Fresenius SE & Co. KGaA, Lupin Limited, Sanzyme, and Merck & Co. Inc., among others.

Additional benefits of purchasing the report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.